CANSINO BIOLOGICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.82 HKD | +2.51% |
|
+14.06% | -20.08% |
| Apr. 22 | Cansino Bio Gets Nod for China Clinical Trials of Haemophilus Influenzae Vaccine | MT |
| Apr. 22 | Cansino Biologics Pneumococcal Vaccine's Phase I Trial Offers Positive Results | MT |
ETFs positioned on CanSino Biologics Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.75% | 4 M€ | -27.92% | ||
| 0.11% | 3 M€ | -0.84% | - | |
| 0.01% | 35 M€ | -5.85% | - | |
| 0.01% | 117 M€ | +1.11% | - | |
| 0.00% | 31 M€ | +3.50% | - | |
| 0.00% | 34 M€ | +6.71% | - | |
| 0.00% | 7 M€ | +1.95% | - | |
| 0.00% | 389 M€ | +6.83% | - | |
| 0.00% | 39 M€ | +3.67% | - | |
| 0.00% | 302 M€ | +3.80% | - | |
| 0.00% | 34 M€ | +2.14% | - | |
| 0.00% | 17 M€ | +1.44% | - | |
| 0.00% | 108 M€ | +2.03% | - | |
| 0.00% | 52 M€ | -0.60% | - | |
| 0.00% | 8 M€ | -0.60% | - |
CanSino Biologics Inc is a clinical-stage vaccine company in China. The Company's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.
Sector
Pharmaceuticals
Calendar
2024-04-28
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
17.42
CNY
Average target price
24.32
CNY
Spread / Average Target
+39.63%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.08% | 1.1B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.35B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- 6185 Stock
- Funds and ETFs CanSino Biologics Inc.
